A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants

NCT05984251 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Vasculitis
Systemic Lupus Erythematosus (SLE)

Interventions

DRUG: CCX168
DRUG: Placebo

Sponsor

Amgen